ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,448,453, issued on Oct. 21, was assigned to Nanjing IASO Biotechnology Co. Ltd. (Nanjing, China).
"Fully human anti-human CD22 chimeric antigen receptor and application thereof" was invented by Guang Hu (Nanjing, China), Yongkun Yang (Nanjing, China), Panpan Niu (Nanjing, China), Guangrong Meng (Nanjing, China), Wei Cheng (Nanjing, China) and Jialu Mo (Nanjing, China).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides an anti-CD22 antibody molecule and a CD22-targeted chimeric antigen receptor (CAR) constructed using the anti-CD22 antibody molecule. The present invention also provides an application of the anti-CD22 antibody mo...